<DOC>
	<DOC>NCT00697450</DOC>
	<brief_summary>This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins</brief_summary>
	<brief_title>Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 2 diabetes Current treatment with insulin NPH or glargine The selection of the subjects will be at the discretion of the individual physician Current treatment with insulin detemir Previous enrolment in this study Hypersensitivity to insulin detemir or to any of the excipients. Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>